DSIP

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide composed of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that plays a role in regulating sleep architecture, stress response, and neuroendocrine function.

First isolated in the 1970s from the cerebral venous blood of sleeping rabbits, it is believed to promote slow-wave (delta) sleep and modulate neurotransmitters and stress hormones like cortisol.

Although DSIP has been studied for potential therapeutic uses in insomnia, pain management, opioid withdrawal, and neuroprotection, it is not FDA-approved for any medical use.

Key characteristics of DSIP include:

• Mechanism: It may influence delta wave sleep, normalize circadian rhythms, and interact with the HPA axis to reduce stress-induced sleep disruption.
• Availability: It is not prescribed in licensed medical settings but is available from suppliers as a “research peptide,” often via injection
• Misconceptions: While some claim it aids detox or treats addiction, it does not replace evidence-based treatments like buprenorphine or methadone, and its ability to treat opioid dependence is not supported by strong clinical evidence.